China National Pharmaceutical Group (SINOPHARM) is the largest pharmaceutical company in the world's most populous nation. The company researches and develops, manufactures, distributes, and markets medicine and other healthcare products. SINOPHARM manages factories, research laboratories, traditional Chinese medicine plantations, and marketing and distribution networks that extend throughout the country. It also has 10 subsidiaries and a number of major joint ventures. The company also runs about a dozen retail pharmacy chains. SINOPHARM, which has operations in Africa, France, Germany, Hong Kong, the US, and Vietnam, was formed in 1998. The Chinese government controls the pharmaceutical firm.

The Government Pharmaceutical Organization (GPO) provides the medicine that keeps Thai residents healthy. The organization researches and manufactures a wide variety of pharmaceutical products for ailments involving the respiratory, cardiovascular, and gastrointestinal systems, and vaccines, among others. GPO also makes vitamins, supplements, and diagnostic test kits. The organization's more than hundreds of pharmacists offer services through its about a dozen facilities, including retail drug stores. The Government Pharmaceutical Laboratories and the Division of Medical Depot merged to form GPO in 1966. The organization is part of Thailand's Ministry of Public Health.

Micromet, Inc. (Micromet) is a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. Four of the Company's antibodies are in clinical trials, while the remainder of its product pipeline is in pre-clinical development. The Company’s BiTE antibody blinatumomab, known as MT103, is being evaluated in a phase II clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase I clinical trial for the treatment of patients with non-Hodgkin’s lymphoma (NHL). A second BiTE antibody, MT110, is being tested in a phase I clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule (EpCAM), which is over-expressed in many solid tumors.

Perrigo Company was founded in 1887 and is headquartered in Allegan, Michigan. Perrigo Company is a global healthcare supplier that develops, manufactures and distributes over-the-counter and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients, and pharmaceutical and medical diagnostic products. The Company operates in three segments: Consumer Healthcare, Rx Pharmaceuticals and API. The Company has other category that consists of the Israel Pharmaceutical and Diagnostic Products. The Company operates through wholly owned subsidiaries. In the United States, its operations are conducted through L. Perrigo Company, Perrigo Company of South Carolina, Inc., Perrigo New York, Inc., Perrigo Holland, Inc. and Perrigo Florida, Inc. Outside the United States, its operations are conducted through Perrigo Israel Pharmaceuticals Ltd., Chemagis Ltd., Quimica y Farmacia S.A. de C.V., Laboratorios Diba, S.A., Wrafton Laboratories Limited, Brunel Pharma Limited and Galpharm Healthcare Ltd.

Alseres Pharmaceuticals, Inc. was founded in 1972 and is headquartered in Hopkinton, Massachusetts. The biotechnology company is developing therapies and diagnostics related to nervous system conditions, such as spinal cord injury, Parkinson's disease, and attention deficit hyperactivity disorder (ADHD). Its lead candidate is Altropane, a molecular imaging agent for diagnosing Parkinson's disease and ADHD. Another candidate, Cethrin, aims to repair nerve damage caused by spinal cord injury; Alseres licensed Cethrin from Canadian firm BioAxone Therapeutic in 2006.

Applied Genetic Technologies Corporation company was formed in 1999; funding partners include InterWest Partners, InterSouth Partners, and MedImmune Ventures. Applied Genetic Technologies Corporation (AGTC) applies itself to developing gene therapies for acquired and inherited genetic diseases. Its lead product is a treatment for Alpha One Antitrypsin Deficiency, which is an inherited cause of emphysema that is the most common hereditary disease in the Western World. Aside from causing lung disease in adults, it can also lead to liver disease in children. AGTC is also developing a treatment for Leber Congenital Amaurosis, which causes blindness, in collaboration with the universities of Florida and Pennsylvania, and Cornell University.

Volu-Sol Reagents Corp company manufactures diagnostic products for use by clinical laboratories; it also plans to provide personal emergency response products and services for consumers. The company's diagnostic business develops and manufactures chemical reagents, stains, and related equipment used by laboratories to detect certain properties in biological samples in fields such as hematology and microbiology. Volu-Sol's yet to be launched Insight Care services employ biosensors, cell phone, and GPS technology to remotely monitor a client's vital signs and provide assistance. Parent RemoteMDx is spinning off Volu-Sol to shareholders. Founded in 1991, ActiveCare (formerly Volu-Sol) has been aided by some of the world’s largest companies, including Matsushita Electric Works (Panasonic), which was not only an investor in the company, but has helped to shape its technologies.

Cumberland Pharmaceuticals was founded in 1999 and is headquartered in Nashville, Tennessee. Cumberland Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets. The company's lead product candidate, Amelior, which is in phase III clinical trials, is an intravenous formulation of ibuprofen for the treatment of both pain and fever. Its products also comprise Acetadote, an intravenous formulation of N-acetylcysteine for the treatment of acetaminophen poisoning; and Kristalose, a prescription laxative product, which is a crystalline form of lactulose to enhance patient acceptance and compliance. In addition, the company is developing a treatment for fluid buildup in the lungs of cancer patients and an anti-infective for treating fungal infections in immuno-compromised patients.

Blansett Pharmacal Co., Inc. company's products include respiratory drugs Prolex and Nalex, tension headache remedy Anolor, and swimmer's ear treatment Cortane. Blansett also makes medications for women's health and hemorrhoids. On top of developing its own products, the company markets under-promoted products developed by other pharmaceutical companies. Blansett Pharmacal was founded in 1982 in North Little Rock, Arkansas; its products are distributed throughout the US.

PLIVA wants you to remember its scientific research and business acumen, and less the names of its products. PLIVA company develops and produces generic pharmaceuticals, particularly in the anti-inflammatory and anti-infective areas. PLIVA also produces the active pharmaceutical ingredients used by other drug makers. Its products include both prescription and over-the-counter drugs, pills, creams, and injectables. PLIVA was founded in 1921 and operates in more than 30 countries. The company is a subsidiary of global generics firm Teva Pharmaceutical.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.